DexCom Operating Expenses 2010-2024 | DXCM

DexCom operating expenses for the twelve months ending September 30, 2024 were $3.326B, a 14.82% increase year-over-year.

  • DexCom annual operating expenses for 2023 were $3.025B, a 20.09% increase from 2022.
  • DexCom annual operating expenses for 2022 were $2.519B, a 15.39% increase from 2021.
  • DexCom annual operating expenses for 2021 were $2.183B, a 34.14% increase from 2020.

DexCom Operating Expenses 2010-2024 | DXCM

  • DexCom annual operating expenses for 2023 were $3.025B, a 20.09% increase from 2022.
  • DexCom annual operating expenses for 2022 were $2.519B, a 15.39% increase from 2021.
  • DexCom annual operating expenses for 2021 were $2.183B, a 34.14% increase from 2020.
Related Stocks
Company NameMarket
Cap
Thermo Fisher Scientific (TMO)$196.3B
Intuitive Surgical (ISRG)$195.1B
Alcon (ALC)$42.4B
Edwards Lifesciences (EW)$41.6B
IQVIA Holdings (IQV)$36.6B
IDEXX Laboratories (IDXX)$34.2B
Waters (WAT)$22.2B
STERIS (STE)$21.2B
SONOVA HOLDING (SONVY)$20.8B
Hologic (HOLX)$18.3B
Fresenius Medical Care AG KGaA (FMS)$13B
Sysmex ADR (SSMXY)$12.9B
Globus Medical (GMED)$11.5B
Penumbra (PEN)$9.4B
Masimo (MASI)$9.3B
Teleflex (TFX)$8.9B
Glaukos (GKOS)$7.9B
PROCEPT BioRobotics (PRCT)$4.9B
Integer Holdings (ITGR)$4.6B
Veracyte (VCYT)$3.1B
Inari Medical (NARI)$2.9B
LivaNova (LIVN)$2.8B
TransMedics (TMDX)$2.6B
Nihon Kohden (NHNKY)$2.5B
Elekta AB (EKTAY)$2.2B
Tandem Diabetes Care (TNDM)$2B
Integra LifeSciences Holdings (IART)$1.8B
RxSight (RXST)$1.8B
Alphatec Holdings (ATEC)$1.4B
Artivion (AORT)$1.2B